Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2485642 | Journal of Pharmaceutical Sciences | 2012 | 11 Pages |
Abstract
AF03 is a squaleneâbased emulsion adjuvant that is present in the adjuvanted pandemic influenza vaccine, Humenzaâ¢. In this report, we describe the design and development of this novel adjuvant formulation from the selection of the oil and surfactant system used in the adjuvant composition to the phase inversion temperature emulsification process that afforded AF03 as a longâterm stable and well calibrated oilâinâwater emulsion. The emulsion was characterized by its particle sizes, surface and interfacial tensions, viscosity, and longâterm stability.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
MarieâFrançoise Klucker, François Dalençon, Patricia Probeck, Jean Haensler,